Related references
Note: Only part of the references are listed.Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient L-amino acid-defined diet in rats
Yuka Hayashizaki-Someya et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
Stephan A. Veltkamp et al.
CLINICAL DRUG INVESTIGATION (2013)
Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus
Vivian A. Fonseca et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
Eiji Kurosaki et al.
PHARMACOLOGY & THERAPEUTICS (2013)
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Takamasa Ohki et al.
SCIENTIFIC WORLD JOURNAL (2012)
Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
Tomoyuki Iwasaki et al.
HEPATO-GASTROENTEROLOGY (2011)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
Richard K. Sterling et al.
HEPATOLOGY (2006)
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
E Bugianesi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease
F Angelico et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
JD Browning et al.
HEPATOLOGY (2004)
Nonalcoholic Fatty Liver Disease: A Review of Current Understanding and Future Impact
Michael Charlton
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
JB Dixon et al.
HEPATOLOGY (2004)
Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review
RT Wang et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
G Marchesini et al.
DIABETES (2001)
Share Paper
